Patrick K. Riggs, M.D.; Denial of Application, 71959-71960 [E7-24608]
Download as PDF
Federal Register / Vol. 72, No. 243 / Wednesday, December 19, 2007 / Notices
methamphetamine traffickers,’’ and
which has ‘‘been disproportionately
represented in clandestine lab seizures
around the United States.’’ T. Young
Associates, Inc., 71 FR 60567, 60568
(2006) (int. quotations and citation
omitted). See also H & R Corp., 71 FR
30168, 30169 (2006); Joy’s Ideas, 70 FR
at 33197. Moreover, a substantial
number of the invoices suggest that
Respondent’s customers purchased
quantities of these products that far
exceeded legitimate demand. This factor
thus further supports the conclusion
that Respondent’s registration would be
‘‘inconsistent with the public interest.’’
21 U.S.C. 823(h).
Order
Accordingly, pursuant to the
authority vested in me by 21 U.S.C.
823(h), as well as 28 CFR 0.100(b) and
0.104, I order that the application of MB
Wholesale, Inc., for a DEA Certificate of
Registration to distribute list I
chemicals, be, and it hereby is, denied.
This order is effective January 18, 2008.
Dated: December 7, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–24610 Filed 12–18–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Patrick K. Riggs, M.D.; Denial of
Application
On June 19, 2007, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Patrick K. Riggs
(Respondent), of Fort Worth, Texas. The
Show Cause Order proposed the denial
of Respondent’s pending application for
a DEA Certificate of Registration as a
practitioner, on the ground that his
registration would be ‘‘inconsistent with
the public interest.’’ Show Cause Order
at 1 (citing 21 U.S.C. 823(f) & 824(a)(4)).
The Show Cause Order specifically
alleged that ‘‘from May 2005 through
August 2006 [Respondent], ordered
22,500 dosage units of hydrocodone
from Henry Schein, Inc.,’’ and that
notwithstanding his ‘‘assertions to
Henry Schein, Inc., that [he was]
practicing medicine during that period
[Respondent], subsequently admitted to
DEA Diversion Investigators that [he]
had not practiced medicine since 1997
and had no current patients.’’ Id. The
Show Cause Order alleged that on
August 31, 2006, Respondent had met
with DEA Diversion Investigators at his
VerDate Aug<31>2005
21:40 Dec 18, 2007
Jkt 214001
home and admitted to them that he had
consumed all of the hydrocodone drugs
that he had obtained from Henry
Schein, Inc. Id.
The Show Cause Order further alleged
that Respondent did not maintain the
purchasing and dispensing records
required under federal law for the
controlled substances he had obtained
from Henry Schein, Inc. Id. Finally, the
Show Cause Order alleged that during
the aforementioned meeting with DEA
investigators, Respondent had upon the
advice of counsel, voluntarily
surrendered his DEA Registration and
agreed not to apply for a new
registration for a two-year period. Id. at
2.
On June 25, 2007, the Show Cause
Order, which also notified Respondent
of his right to request a hearing on the
allegations, was served on him by a
Federal Express delivery to his
residence, which is also the address of
his proposed registered location.
Because: (1) More than thirty days have
passed since service of the Show Cause
Order, and (2) neither Respondent, nor
anyone purporting to represent him, has
requested a hearing, I conclude that
Respondent has waived his right to a
hearing. See 21 CFR 1301.43(d). I
therefore enter this Final Order without
a hearing based on relevant material
contained in the investigative file, see
id. 1301.43(e), and make the following
findings.
Findings
Respondent previously held a DEA
Registration as a practitioner, which
authorized him to dispense controlled
substances in schedules II through V.
On various dates between May 2005 and
August 2006, DEA received several
reports from Henry Schein, Inc.,
regarding Respondent’s excessive
purchases of controlled substances.
These reports showed that during the
above period, Respondent purchased
22,500 dosage units of combination
hydrocodone/acetaminophen (all in 10/
325 mg. strength), 1400 dosage units of
clonazepam (in both 1 mg. and 2 mg.
strength), 1200 dosage units of aspirin
with codeine (60 mg.), 500 dosage units
of acetaminophen with codeine (60
mg.), and hydrocodone with ibuprofen
(7.5/200 mg.).1
Sometime around September 2005, a
Schein employee apparently questioned
Respondent regarding his purchases.
Accordingly, on September 24, 2005,
Respondent faxed a letter which stated
that he had served as ‘‘a consultant to
1 The
reports also showed that Respondent had
purchased two anabolic steroids, nandrolone and
testosterone cypionate.
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
71959
the TXSBME’’ 2 from 1995 through 1998
‘‘in the area of disciplinary action,’’ and
had ‘‘earned * * * a great many
enemies (because of my testimony in
med[ical] malpractice cases for the
state.’’ Respondent further wrote that he
was engaged in the practice of ‘‘general
medicine,’’ and that his ‘‘patient base is
select. The concentration is chronic
pain secondary to terminal illness[,] i.e.,
cancer.’’
On August 31, 2006, DEA
investigators went to Respondent’s
residence (and registered location) and
met with Respondent and his attorney
regarding his excessive purchases.
During the interview, Respondent was
asked what medications he took.
Respondent went to another room and
retrieved approximately twenty-five
containers of non-controlled
prescription drugs. Upon further
questioning, Respondent admitted that
he had been on methadone and pulled
an empty container of methadone from
his pocket.
During the interview, Respondent also
admitted that he had not practiced
medicine since 1997 and did not have
any patients. One of the investigators
then presented to Respondent’s attorney
a spreadsheet listing his controlled
substance purchases from Schein. After
Respondent and his lawyer were
allowed to privately discuss the matter,
Respondent admitted that he had used
all of the controlled substances which
he had purchased from Schein.
Respondent also stated that to prevent
damaging his liver, he had ground up
the hydrocodone tablets to separate out
the acetaminophen. Respondent also
admitted that he had failed to maintain
purchasing and dispensing records as
required by Federal law.
Based on this information, the
investigators advised Respondent’s
counsel that they would seek an Order
to Show Cause to revoke his registration
unless he voluntarily surrendered it.
After consulting with his attorney,
Respondent voluntarily surrendered his
registration and signed the applicable
form.3
Two months later, on October 30,
2006, Respondent submitted an
application for a new registration. On
the form, Respondent acknowledged
that he had surrendered his registration
and explained that ‘‘[t]he surrender[]
could be classified as a
misunderstanding secondary to
misinformation. I view it[] as an
unusual set of unnecessary and
2 Presumably, the Texas State Board of Medical
Examiners.
3 On the form, Respondent also ‘‘agree[d] not to
re apply for a period of two years.’’
E:\FR\FM\19DEN1.SGM
19DEN1
71960
Federal Register / Vol. 72, No. 243 / Wednesday, December 19, 2007 / Notices
humiliating circumstances brought
together by a malicious third party.’’
Discussion
Section 303(f) of the Controlled
Substances Act provides that ‘‘[t]he
Attorney General shall register
practitioners * * * to dispense * * *
controlled substances in schedule II, III,
IV, or V, if the applicant is authorized
to dispense * * * controlled substances
under the laws of the State in which he
practices.’’ 21 U.S.C. 823(f). Section
303(f) further provides that ‘‘[t]he
Attorney General may deny an
application for such registration if he
determines that the issuance of such
registration would be inconsistent with
the public interest.’’ Id. In making the
public interest determination, the Act
requires the consideration of the
following factors:
mstockstill on PROD1PC66 with NOTICES
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing * * * controlled substances.
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
Id.
[T]hese factors are * * * considered
in the disjunctive.’’ Robert A. Leslie,
M.D., 68 FR 15227, 15230 (2003). I ‘‘may
rely on any one or a combination of
factors, and may give each factor the
weight [I] deem[] appropriate in
determining whether a registration
should be revoked.’’ Id. Moreover, I am
‘‘not required to make findings as to all
of the factors.’’ Hoxie v. DEA, 419 F.3d
477, 482 (6th Cir. 2005); see also Morall
v. DEA, 412 F.3d 165, 173–74 (D.C. Cir.
2005). In this case, I conclude that
factors two and four are dispositive.4
As the record demonstrates,
Respondent acquired large quantities of
controlled substances including 22,500
tablets of combination hydrocodone/
acetaminophen (a schedule III
controlled substance, 21 CFR
1308.13(e)), 1400 dosage units of
clonazepam (a schedule IV controlled
substance, 21 CFR 1308.14(c)), as well
as drugs combining codeine with
acetaminophen or aspirin. Respondent
admitted that he personally used the
drugs.
The record also shows that on
September 24, 2005, Respondent
represented to an employee of Henry
4 Having considered all of the factors, I conclude
that factors one, three and five are not relevant.
VerDate Aug<31>2005
21:40 Dec 18, 2007
Jkt 214001
Schein, Inc., that he was ‘‘practic[ing]
general medicine,’’ with a
‘‘concentration in chronic pain
secondary to terminal illness, i.e.,
cancer.’’ During the August 31, 2006
interview, however, Respondent
admitted that he had not practiced
medicine since 1997 and that he had no
patients. The record further shows that
after he faxed the letter to Schein,
Respondent continued to order and
received large quantities of controlled
substances from it. Based on this
evidence, I conclude that on numerous
occasions, Respondent violated federal
law by ‘‘knowingly or intentionally
* * * acquir[ing] or obtain[ing]
possession of a controlled substance by
misrepresentation, fraud, [or]
deception.’’ 21 U.S.C. 843(a)(3).
Respondent further admitted that he
did not maintain the purchasing and
dispensing records as required by
federal law. See id. § 827(a)(3). Based on
the above, I conclude that Respondent’s
record of non-compliance with federal
laws related to controlled substances
and his experience of self-dispensing
controlled substances, establishes that
granting him a registration would be
‘‘inconsistent with the public interest.’’
Id. § 823(f).
Order
Consequently, the investigation has
been terminated.
Signed at Washington, DC, this 12th day of
December, 2007.
Linda G. Poole,
Certifying Officer, Division of Trade
Adjustment Assistance.
[FR Doc. E7–24544 Filed 12–18–07; 8:45 am]
BILLING CODE 4510–FN–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–62,510 and TA–W–62,510A]
Cuno, Inc., Meriden, CT and Enfield,
CT; Notice of Termination of
Investigation
Pursuant to Section 221 of the Trade
Act of 1974, as amended, an
investigation was initiated on November
29, 2007 in response to a petition filed
by a State agency representative on
behalf of workers of two locations of
Cuno, Inc., namely Meriden,
Connecticut (TA–W–62,510) and
Enfield, Connecticut (TA–W–62,510A).
The petitioner has requested that the
petition be withdrawn. Consequently,
the investigation has been terminated.
Pursuant to the authority vested in me
by 21 U.S.C. 823(f), as well as 28 CFR
0.100(b) & 0.104, I order that the
application of Patrick K. Riggs, M.D., for
a DEA Certificate of Registration as a
practitioner be, and it hereby is, denied.
This order is effective January 18, 2008.
Signed in Washington, DC, this 13th day of
December 2007.
Linda G. Poole,
Certifying Officer, Division of Trade
Adjustment Assistance.
[FR Doc. E7–24546 Filed 12–18–07; 8:45 am]
Dated: December 7, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–24608 Filed 12–18–07; 8:45 am]
DEPARTMENT OF LABOR
BILLING CODE 4410–09–P
BILLING CODE 4510–FN–P
Employment and Training
Administration
[TA–W–62,426]
DEPARTMENT OF LABOR
Flextronics Enclosures, Including OnSite Leased Workers of Manpower and
Coast Personnel, Youngsville, NC;
Notice of Termination of Investigation
Employment and Training
Administration
[TA–W–62,418]
Computer Sciences Corporation,
Dallas, Texas; Notice of Termination of
Investigation
Pursuant to section 221 of the Trade
Act of 1974, as amended, an
investigation was initiated on November
6, 2007 in response to a petition filed by
a company official on behalf of workers
of Computer Sciences Corporation,
Dallas, Texas.
The company official has requested
that the petition be withdrawn.
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
Pursuant to section 221 of the Trade
Act of 1974, as amended, an
investigation was initiated on November
7, 2007, in response to a worker petition
filed on behalf of workers at Flextronics
Enclosures, Youngsville, North
Carolina.
The petitioning group of workers is
covered by an active certification, (TA–
W–62,486) which expires on November
7, 2009. Consequently, further
investigation in this case would serve
no purpose, and the investigation has
been terminated.
E:\FR\FM\19DEN1.SGM
19DEN1
Agencies
[Federal Register Volume 72, Number 243 (Wednesday, December 19, 2007)]
[Notices]
[Pages 71959-71960]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-24608]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Patrick K. Riggs, M.D.; Denial of Application
On June 19, 2007, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Patrick K. Riggs (Respondent), of Fort Worth, Texas. The
Show Cause Order proposed the denial of Respondent's pending
application for a DEA Certificate of Registration as a practitioner, on
the ground that his registration would be ``inconsistent with the
public interest.'' Show Cause Order at 1 (citing 21 U.S.C. 823(f) &
824(a)(4)).
The Show Cause Order specifically alleged that ``from May 2005
through August 2006 [Respondent], ordered 22,500 dosage units of
hydrocodone from Henry Schein, Inc.,'' and that notwithstanding his
``assertions to Henry Schein, Inc., that [he was] practicing medicine
during that period [Respondent], subsequently admitted to DEA Diversion
Investigators that [he] had not practiced medicine since 1997 and had
no current patients.'' Id. The Show Cause Order alleged that on August
31, 2006, Respondent had met with DEA Diversion Investigators at his
home and admitted to them that he had consumed all of the hydrocodone
drugs that he had obtained from Henry Schein, Inc. Id.
The Show Cause Order further alleged that Respondent did not
maintain the purchasing and dispensing records required under federal
law for the controlled substances he had obtained from Henry Schein,
Inc. Id. Finally, the Show Cause Order alleged that during the
aforementioned meeting with DEA investigators, Respondent had upon the
advice of counsel, voluntarily surrendered his DEA Registration and
agreed not to apply for a new registration for a two-year period. Id.
at 2.
On June 25, 2007, the Show Cause Order, which also notified
Respondent of his right to request a hearing on the allegations, was
served on him by a Federal Express delivery to his residence, which is
also the address of his proposed registered location. Because: (1) More
than thirty days have passed since service of the Show Cause Order, and
(2) neither Respondent, nor anyone purporting to represent him, has
requested a hearing, I conclude that Respondent has waived his right to
a hearing. See 21 CFR 1301.43(d). I therefore enter this Final Order
without a hearing based on relevant material contained in the
investigative file, see id. 1301.43(e), and make the following
findings.
Findings
Respondent previously held a DEA Registration as a practitioner,
which authorized him to dispense controlled substances in schedules II
through V. On various dates between May 2005 and August 2006, DEA
received several reports from Henry Schein, Inc., regarding
Respondent's excessive purchases of controlled substances. These
reports showed that during the above period, Respondent purchased
22,500 dosage units of combination hydrocodone/acetaminophen (all in
10/325 mg. strength), 1400 dosage units of clonazepam (in both 1 mg.
and 2 mg. strength), 1200 dosage units of aspirin with codeine (60
mg.), 500 dosage units of acetaminophen with codeine (60 mg.), and
hydrocodone with ibuprofen (7.5/200 mg.).\1\
---------------------------------------------------------------------------
\1\ The reports also showed that Respondent had purchased two
anabolic steroids, nandrolone and testosterone cypionate.
---------------------------------------------------------------------------
Sometime around September 2005, a Schein employee apparently
questioned Respondent regarding his purchases. Accordingly, on
September 24, 2005, Respondent faxed a letter which stated that he had
served as ``a consultant to the TXSBME'' \2\ from 1995 through 1998
``in the area of disciplinary action,'' and had ``earned * * * a great
many enemies (because of my testimony in med[ical] malpractice cases
for the state.'' Respondent further wrote that he was engaged in the
practice of ``general medicine,'' and that his ``patient base is
select. The concentration is chronic pain secondary to terminal
illness[,] i.e., cancer.''
---------------------------------------------------------------------------
\2\ Presumably, the Texas State Board of Medical Examiners.
---------------------------------------------------------------------------
On August 31, 2006, DEA investigators went to Respondent's
residence (and registered location) and met with Respondent and his
attorney regarding his excessive purchases. During the interview,
Respondent was asked what medications he took. Respondent went to
another room and retrieved approximately twenty-five containers of non-
controlled prescription drugs. Upon further questioning, Respondent
admitted that he had been on methadone and pulled an empty container of
methadone from his pocket.
During the interview, Respondent also admitted that he had not
practiced medicine since 1997 and did not have any patients. One of the
investigators then presented to Respondent's attorney a spreadsheet
listing his controlled substance purchases from Schein. After
Respondent and his lawyer were allowed to privately discuss the matter,
Respondent admitted that he had used all of the controlled substances
which he had purchased from Schein. Respondent also stated that to
prevent damaging his liver, he had ground up the hydrocodone tablets to
separate out the acetaminophen. Respondent also admitted that he had
failed to maintain purchasing and dispensing records as required by
Federal law.
Based on this information, the investigators advised Respondent's
counsel that they would seek an Order to Show Cause to revoke his
registration unless he voluntarily surrendered it. After consulting
with his attorney, Respondent voluntarily surrendered his registration
and signed the applicable form.\3\
---------------------------------------------------------------------------
\3\ On the form, Respondent also ``agree[d] not to re apply for
a period of two years.''
---------------------------------------------------------------------------
Two months later, on October 30, 2006, Respondent submitted an
application for a new registration. On the form, Respondent
acknowledged that he had surrendered his registration and explained
that ``[t]he surrender[] could be classified as a misunderstanding
secondary to misinformation. I view it[] as an unusual set of
unnecessary and
[[Page 71960]]
humiliating circumstances brought together by a malicious third
party.''
Discussion
Section 303(f) of the Controlled Substances Act provides that
``[t]he Attorney General shall register practitioners * * * to dispense
* * * controlled substances in schedule II, III, IV, or V, if the
applicant is authorized to dispense * * * controlled substances under
the laws of the State in which he practices.'' 21 U.S.C. 823(f).
Section 303(f) further provides that ``[t]he Attorney General may deny
an application for such registration if he determines that the issuance
of such registration would be inconsistent with the public interest.''
Id. In making the public interest determination, the Act requires the
consideration of the following factors:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing * * * controlled
substances.
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
[T]hese factors are * * * considered in the disjunctive.'' Robert
A. Leslie, M.D., 68 FR 15227, 15230 (2003). I ``may rely on any one or
a combination of factors, and may give each factor the weight [I]
deem[] appropriate in determining whether a registration should be
revoked.'' Id. Moreover, I am ``not required to make findings as to all
of the factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005); see
also Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005). In this
case, I conclude that factors two and four are dispositive.\4\
---------------------------------------------------------------------------
\4\ Having considered all of the factors, I conclude that
factors one, three and five are not relevant.
---------------------------------------------------------------------------
As the record demonstrates, Respondent acquired large quantities of
controlled substances including 22,500 tablets of combination
hydrocodone/acetaminophen (a schedule III controlled substance, 21 CFR
1308.13(e)), 1400 dosage units of clonazepam (a schedule IV controlled
substance, 21 CFR 1308.14(c)), as well as drugs combining codeine with
acetaminophen or aspirin. Respondent admitted that he personally used
the drugs.
The record also shows that on September 24, 2005, Respondent
represented to an employee of Henry Schein, Inc., that he was
``practic[ing] general medicine,'' with a ``concentration in chronic
pain secondary to terminal illness, i.e., cancer.'' During the August
31, 2006 interview, however, Respondent admitted that he had not
practiced medicine since 1997 and that he had no patients. The record
further shows that after he faxed the letter to Schein, Respondent
continued to order and received large quantities of controlled
substances from it. Based on this evidence, I conclude that on numerous
occasions, Respondent violated federal law by ``knowingly or
intentionally * * * acquir[ing] or obtain[ing] possession of a
controlled substance by misrepresentation, fraud, [or] deception.'' 21
U.S.C. 843(a)(3).
Respondent further admitted that he did not maintain the purchasing
and dispensing records as required by federal law. See id. Sec.
827(a)(3). Based on the above, I conclude that Respondent's record of
non-compliance with federal laws related to controlled substances and
his experience of self-dispensing controlled substances, establishes
that granting him a registration would be ``inconsistent with the
public interest.'' Id. Sec. 823(f).
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f), as well
as 28 CFR 0.100(b) & 0.104, I order that the application of Patrick K.
Riggs, M.D., for a DEA Certificate of Registration as a practitioner
be, and it hereby is, denied. This order is effective January 18, 2008.
Dated: December 7, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7-24608 Filed 12-18-07; 8:45 am]
BILLING CODE 4410-09-P